GSK Divests China Suzhou Site, Antiviral Rights To Fosun

 
• By Brian Yang

GSK becomes latest pharma multinational to offload assets in China as competition and pricing pressure continue to mount.

China - Suzhou City
GSK DIVESTS SUZHOU PRODUCTION SITE AND LAMIVUDINE RIGHTS TO FOSUN • Source: Shutterstock

More from China

More from Focus On Asia